{
  "docId": "019de076-bddf-713d-b5c2-6a8995d43cc7",
  "docSlug": "296d0f6148994ebf1cf19bb1f2080f15",
  "documentTitle": "AbCellera | Investor Presentation Deck | 22 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 22,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a table to show the status of two specific molecules (ABCL635 and ABCL575) in the IND-enabling phase.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-bddf-713d-b5c2-6a8995d43cc7/6",
  "deckHref": "/decks/019de076-bddf-713d-b5c2-6a8995d43cc7",
  "deckJsonHref": "/decks/019de076-bddf-713d-b5c2-6a8995d43cc7.json",
  "deckAnchorHref": "/decks/019de076-bddf-713d-b5c2-6a8995d43cc7#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.58,
        "y": 0.12
      },
      "kind": "list",
      "text": "First two IND submissions anticipated in 2025; We intend to take additional first-in-class development candidates into IND-enabling studies in 2024 and 2025; $220M in non-dilutive funding from the governments of Canada and British Columbia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00323ae1-27dd-4656-abbd-9fca9b4e54a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.83,
        "x": 0.097,
        "y": 0.45
      },
      "kind": "table",
      "text": "Molecule, Target, Indication, Therapeutic Area, Potential Differentiation; ABCL635, undisclosed GPCR or ion channel, undisclosed, metabolic & endocrine conditions, first in class; ABCL575, OX40L, atopic dermatitis, immunology & inflammation, best in class",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44ddaddc-3afe-467f-bd4a-7014061c9b07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.097,
        "y": 0.12
      },
      "kind": "title",
      "text": "We are advancing an internal pipeline of potential first-in-class and best-in-class assets as a top priority to drive growth.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8023651f-5043-4104-980a-00242cd1dd08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.12,
        "x": 0.097,
        "y": 0.05
      },
      "kind": "title",
      "text": "Our Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26c70577-23b5-4a05-9a04-c6c449993ecb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "c8401c8c-ab1f-4d12-8cf5-dd565fcbdd08",
      "evidence": "We are advancing an internal pipeline of potential first-in-class and best-in-class assets as a top priority to drive growth.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 3,
      "beatId": "4a0f735b-10b9-4f4f-8338-52513ab7cfc6",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The company highlights its evolving business model and investments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "8a8d028a-7c3b-4db3-b468-921b7ae2e2cf",
      "evidence": "The company highlights its investments and progress.",
      "position": 0,
      "objective": "Why now is the right time for AbCellera's evolution",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}